LIZA SHAPIRO STROVINK

Liza Shapiro Strovink stands as a pivotal figure in the landscape of venture philanthropy, serving as the Managing Partner at AllerFund. In this influential role, she is instrumental in shaping the organization's strategic investment portfolio, meticulously identifying and nurturing initiatives poised to revolutionize the field of food allergy research and treatment. AllerFund operates with a unique model, combining philanthropic intent with venture capital rigor to accelerate the development of life-changing solutions for millions affected by food allergies worldwide.

Under Ms. Strovink's leadership, AllerFund's investment focus is sharply honed on high-impact areas within the food allergy ecosystem. This includes pioneering research into novel immunotherapies designed to desensitize individuals to allergens, advanced diagnostic tools for earlier and more accurate detection, and innovative prevention strategies aimed at reducing the incidence of food allergies. She champions investments in early-stage biotech companies, academic research translation, and technology platforms that promise scalable solutions. Her approach emphasizes scientific merit, potential for broad patient impact, and the ability to bridge critical gaps in current understanding and treatment.

Liza Shapiro Strovink brings a wealth of experience and a deep commitment to her role. Her career background is marked by a distinguished tenure in both the venture capital and philanthropic sectors, with a particular emphasis on life sciences and healthcare innovation. Prior to joining AllerFund, she honed her expertise at prominent investment firms, where she specialized in identifying and scaling disruptive technologies in biotechnology and medical devices. This extensive background equipped her with a keen eye for scientific rigor and market potential, skills she now applies to AllerFund's mission-driven investments. Her passion for addressing unmet medical needs, particularly in areas affecting children and families, fuels her dedication to AllerFund's impactful work.

While specific portfolio companies are often confidential or part of broader research grants, AllerFund's strategic allocations under Ms. Strovink's guidance have supported promising ventures exploring microbiome-based therapies for allergy prevention, developing next-generation epinephrine auto-injectors, and advancing personalized medicine approaches for severe allergic reactions. Her leadership ensures that AllerFund remains at the forefront of funding innovation, driving progress towards a future where food allergies are manageable, preventable, and ultimately, curable.